# Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)

> **NCT03963518** · — · COMPLETED · sponsor: **Institut Bergonié** · enrollment: 631 (actual)

## Conditions studied

- Cancer Treated With Immune-checkpoint Inhibitors

## Interventions

- **DRUG:** nivolumab monotherapy
- **DRUG:** nivolumab plus ipilimumab

## Key facts

- **NCT ID:** NCT03963518
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 631 (ACTUAL)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03963518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03963518, "Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03963518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*